HOME > Clinical Trial
As of December 2021
| Subject | Phase II trial of repeated high dose luteal hormone therapy for intrauterine recurrence following fertility preserving therapy for atypical endometrial hyperplasia or endometrial cancer |
|---|---|
| Treatment | Single arm phase II trial:High dose MPA therapy |
| Accrual Period | Jne 2020 - June 2023 |
| Target number of patients | 115 |
| Subject | Patients with surgical stage I epithelial ovarian cancer |
|---|---|
| Treatment | Phase III, randomized, comparative study of surgery plus adjuvant chemotherapy and surgery alone. |
| Accrual Period | July 2012 - June 2024 |
| Target number of patients | Number per group: 230 Total number: 460 |
| Subject | BRCA1 and/or BRCA2 variant carriers |
|---|---|
| Treatment | To determine the incidence and risk factors in the development of ovarian, fallopian tube, and peritoneal cancers in Japanese women carrying BRCA1/2 variants. |
| Accrual Period | April 2017 - March 2027 |
| Target number of patients | 600 |
| Subject | cervical cancer |
|---|---|
| Treatment | To reveal sexuality change after cancer treatment among Japanese cervical cancer patients using Female Sexual Function Index (FSFI) and Hospital Anxiety and Depression Scale (HADS). |
| Accrual Period | September 2018 - August 2019 |
| Target number of patients | 150 |